Inhaled Ciclesonide Study in Preterm Infants
Sponsor: Venkatesh Sampath • ClinicalTrials.gov ID: NCT06589245
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
Interventions
-
Alvesco Inhalant Product
(Drug)
Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.
Eligibility criteria
Conditions
Locations
- Children's Mercy Kansas City — Kansas City, Missouri, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record